Use of 48 Hour Course of Antibiotics to Prevent Surgical Site Infection in Obese Patients Undergoing Cesarean Delivery (SSI)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate if preoperative antibiotics, followed by 48 hour course of broad spectrum antibiotics prevents wound infection complications in patients that are obese who undergo cesarean section. Standard antibiotic prophylaxis in all weight women undergoing cesarean section is cefazolin prior to skin incision. It is the hypothesis that a prolonged, 48 hour course of broad spectrum antibiotics that are suited to prevent growth of normal vaginal flora will decrease the rate of surgical site infection in obese patients that are at a greatly increased risk of postoperative infections complications.
| Condition | Intervention |
|---|---|
|
Surgical Site Infection in Obese Women Undergoing C-section |
Drug: cephalexin & metronidazole Drug: placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Use of 48 Hour Course of Antibiotics to Prevent Surgical Site Infection in Obese Patients Undergoing Cesarean Delivery |
- Surgical site infection [ Time Frame: 6weeks post partum ] [ Designated as safety issue: No ]
- Febrile morbidity; Urinary tract infection; Endometritis [ Time Frame: 6 weeks post partum ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 475 |
| Study Start Date: | September 2010 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Cephalexin and metronidazole
500 mg cephalexin per oral every 8 hours for total of 6 doses; 500 mg metronidazole per oral every 8 hours for total of 6 doses
|
Drug: cephalexin & metronidazole
cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
Other Name: Keflex & Flagyl
|
|
Placebo Comparator: Placebo/standard of care
Placebo pills per oral every 8 hours for total of 6 doses
|
Drug: placebo
placebo representing standard of care
|
Detailed Description:
We propose the conduction of a prospective, randomized, double-blinded clinical trial to evaluate an alternative prophylactic regimen for the prevention of surgical site infection. This study is to be conducted by the Department of Obstetrics at University Hospital. The intervention being studied will be the continuation of cephalexin and metronidazole for 48 hours. The primary outcome measure will be the development of infectious morbidity, including wound infection and endometritis, in the postoperative period.
In order to most effectively and accurately analyze our primary and secondary research outcomes, the investigators will standardize our surgical operation techniques in all ways feasible. These recommendations will be in concordance with American College of Obstetrics and Gynecology recommendations, as those generally accepted in the medical literature. All patients will undergo surgery in the same small group of HEPA filtration and positive air pressure operating rooms. Appropriate limitations on number of surgeons and assistants scrubbed for surgery as well as general OR traffic will be enforced. Patients will undergo hair clipping of the incision site when appropriate. Chlorhexidine skin decontamination will be the standard surgical site preparation. An antimicrobial, adhesive drape will be used. Prior to skin incision, cefazolin will be administered.
All patients to be considered for recruitment to this study will be undergoing delivery at University Hospital. Patients with an elevated BMI > 30 kg/m2 who undergo cesarean section will be considered for randomization either prior to delivery or in the first 7 hours after delivery, to accommodate the need for the first dose of study medication or placebo 8 hours after surgery. Only patients who agree to inclusion after informed consent will be randomized per protocol.
Eligibility| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- BMI > 30kg/m*2
- Delivery via cesarean section
- consent to participate
- age 13 or older
Exclusion Criteria:
- known immunodeficiency syndromes
- non-English speaking
- known allergy to cephalosporins or metronidazole
Contacts and Locations| United States, Ohio | |
| The Univeristy Hospital | |
| Cincinnati, Ohio, United States, 45219 | |
| Principal Investigator: | Carri Warshak, MD | University of Cincinnati |
More Information
Publications:
| Responsible Party: | Rose Maxwell, Ph.D., Director of Clinical Research, University of Cincinnati |
| ClinicalTrials.gov Identifier: | NCT01194115 History of Changes |
| Other Study ID Numbers: | Surgical Site Infection C-Sect |
| Study First Received: | September 1, 2010 |
| Last Updated: | November 10, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Cincinnati:
|
surgical site infection obesity pregnancy cesarean section cesarean delivery |
Additional relevant MeSH terms:
|
Obesity Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Anti-Bacterial Agents Cephalexin |
Metronidazole Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Radiation-Sensitizing Agents Physiological Effects of Drugs Antiprotozoal Agents Antiparasitic Agents |
ClinicalTrials.gov processed this record on May 19, 2013